For pediatric patients with acute lymphoblastic leukemia (ALL), obesity increases risk of persistent disease
the ONA take:
According to a new study published in the journal Blood, obese pediatric patients with acute lymphoblastic leukemia (ALL) are more likely to have minimal residual disease following induction therapy compared with non-obese patients.
Researchers at Childrens Hospital Los Angeles in Los Angeles, California, sought to determine why obese pediatric patients with ALL have worse outcomes compared with non-obese patients. For the study, the team identified 189 pediatric patients diagnosed with ALL. Patients were considered lean if they were classified as being less than 85% body mass index (BMI). Nearly one-third of patients were overweight or obese at the time of initial diagnosis.
To test for minimal residual disease, researchers tested the bone marrow of patients following induction therapy for 2 to 5 years from the time of diagnosis. Results showed that lean patients with minimal residual disease experiences comparable outcomes to obese patients with no evidence of residual disease.
In addition, obese patients with residual disease were observed to have the worst outcomes. Patients that were lean at the time of diagnosis but became obese during the first month of treatment had similar outcomes to patients who remained lean throughout treatment. The findings suggest that obesity increases the risk of persistent disease and alters the interaction between residual ALL cells and chemotherapy.
Obese pediatric patients with ALL are more likely to have minimal residual disease.
Obese youths with acute lymphoblastic leukemia (ALL) are known to have worse outcomes than their lean counterparts. To find out why, investigators at Children's Hospital Los Angeles studied patients who were obese at the time of their diagnosis with ALL to determine if body mass index (BMI) impacted response to initial chemotherapy. This response to initial chemotherapy (or induction therapy) is measured by the absence of leukemia cells in the bone marrow.
Called minimal residual disease (MRD), in which residual leukemia cells cannot be seen under microscope but can be detected by more sensitive methods, it is among the strongest predictors of long-term survival and disease recurrence. As reported in First Edition of the journal Blood on October 27, following induction chemotherapy, obese patients were more than twice as likely to have minimal residual disease, than non-obese patients.
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- G-CSF May Help Preserve Fertility in Male Patients With Cancer
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Patients With HER2-enriched Subtype Benefit Most from Dual HER2 Blockade
- Scalp Cooling Reduces Risk of Chemotherapy-Induced Alopecia
- CRISPR Illustrates Progression of Normal Blood Cells to Leukemia, Precursor Diseases
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|